Research
-
{
- All
- News
- Videos
- Web Stories
-
Diwali Stock Picks 2026: BEL, Shriram Finance Among PL Capital's Eight Recommendations For Samvat 2083; Check Full List
With Dhanteras today and Diwali around the corner, PL Capital has unveiled a basket of eight stock ideas spanning defence, PSU, banks, NBFCs, industrials and consumption sectors including BEL, ICICI Bank, Britannia Industries, and more from large and mid-cap sector.
-
Fractal Analytics, PhysicsWallah, And More Q2 Review: Check PL Capital's Target Prices, Ratings
Among these updates, Samhi Hotels stands out with the highest projected upside of over 34%, supported by robust demand in the hospitality segment, followed closely by Fractal Analytics at 26.8% upside as its AI product business scales rapidly.
-
LIC, Apollo Hospitals Among 15 Stocks In HDFC Securities' Q2 Review, Upside Up To 73%; Check Target Prices
Following September-quarter earnings, HDFC Sec has maintained its postive stance on 15 stocks across ports, including LIC, Apollo Hospitals, Titan Company, Aurobinod Pharma, Ipca Labs, and more.
-
Adani Ports In Focus: Evos Acquisition Makes Motilal Oswal More Optimistic; Check Target Price
Similar to Adani Ports' recent NQXT acquisition, Evos is also backed by a similar take-or-pay arrangement with most of the customers.
-
M&M Q2 Results Impress; Motilal Oswal Raises Estimates On Improving Auto Margins
On the back of its healthy launch pipeline and positive consumer sentiment, M&M provided a strong outlook for FY27E across segments, believes the brokerage.
-
Titan Q2 Review: Target Price Cut Doesn't Diminish Motilal Oswal's Bullish View | Here's Why
The brokerage remains constructive on growth in the jewelry industry, particularly among top players, and believe Titan will remain well-positioned competitively, supported by initiatives such as its exchange program.
-
Diwali Muhurat Picks 2026: Eternal, Titan Among Motilal Oswal's Top 10 Stock Bets For Samvat 2083
For Samvat 2083, the brokerage is positive on BFSI and capital markets, manufacturing, global outsourcing, exports, and consumption and digital. Banks are set for steady loan growth with improving margins, while rising participation supports capital markets segment.
-
Eating More Carbs May Help Reverse Biological Ageing: What A New Study Says
A University of Sydney study found older adults on a low-fat, high-carb omnivorous diet showed improved biological-age markers in four weeks.
-
Redington Gets Motilal Oswal's 'Buy' Initiation, Sees Up To 36% Upside; Check Target Price
Redington is well positioned to capitalise on structural growth in technology distribution, supported by established original equipment manufacturer relationships, an extensive channel network and a diversified geographic presence, believes Motilal Oswal.
-
Mahanagar Gas To Fine Organic Q2 Review: Check Motilal Oswal's New Target Prices, Upside
Following September-quarter earnings, domestic brokerage Motilal Oswal has maintained its ratings on all seven stocks across pharma, building material, retail, oil and gas sector including Mahanagar Gas, GSK Pharma, V2 Retail, Anant Raj, and more with uspide of up to 48%.
-
Nykaa, Zydus Lifesciences And More Q2 Review: HDFC Sec Sees Up To 83% Upside Across 17 Stocks; Check New Target Prices
Following September-quarter earnings, HDFC Sec has maintained its ratings on 17 stocks across pharma, capital markets, financial services, healthcare, retail, chemicals, including Zydus Life, BSE, Nykaa, Lupin, MCX, Sundaram Finance, HG Infra and more.
-
Dabur Q2 Review: Sustaining Earnings Growth Key For Valuations, Says HDFC Securities; Check Target Price
Clear strategic actions under the new leadership will be critical to sustaining the early momentum and supporting Dabur's valuation recovery, says the brokerage.
-
Lenskart Q2 Review: Motilal Oswal Raises Target Price As Growth, Margins Improve
India revenue growth accelerated to 35% YoY driven by robust same-store sales growth and store additions, while Lenskart's international business delivered a strong quarter.
-
Lupin Q2 Review: Systematix Revises Target Price, Remains Cautious On US Recovery
While the growing complex generics, injectables and biosimilars pipeline provides medium-term growth visibility, Systematix remain cautious on Lupin's near-term US trajectory, given continued competitive intensity in Tolvaptan and Mirabegron.
-
Delhi HC Issues Notice On Plea Seeking Time-Bound Safety Review Of Acidity Drug Ranitidine
The Delhi High Court on Wednesday issued notice on a Public Interest Litigation (PIL) seeking a time-bound and reasoned decision by the Centre on the safety of Ranitidine, a widely used acidity medication, amid concerns over the possible presence of a cancer-linked impurity in the drug.
-
Diwali Stock Picks 2026: BEL, Shriram Finance Among PL Capital's Eight Recommendations For Samvat 2083; Check Full List
With Dhanteras today and Diwali around the corner, PL Capital has unveiled a basket of eight stock ideas spanning defence, PSU, banks, NBFCs, industrials and consumption sectors including BEL, ICICI Bank, Britannia Industries, and more from large and mid-cap sector.
-
Fractal Analytics, PhysicsWallah, And More Q2 Review: Check PL Capital's Target Prices, Ratings
Among these updates, Samhi Hotels stands out with the highest projected upside of over 34%, supported by robust demand in the hospitality segment, followed closely by Fractal Analytics at 26.8% upside as its AI product business scales rapidly.
-
LIC, Apollo Hospitals Among 15 Stocks In HDFC Securities' Q2 Review, Upside Up To 73%; Check Target Prices
Following September-quarter earnings, HDFC Sec has maintained its postive stance on 15 stocks across ports, including LIC, Apollo Hospitals, Titan Company, Aurobinod Pharma, Ipca Labs, and more.
-
Adani Ports In Focus: Evos Acquisition Makes Motilal Oswal More Optimistic; Check Target Price
Similar to Adani Ports' recent NQXT acquisition, Evos is also backed by a similar take-or-pay arrangement with most of the customers.
-
M&M Q2 Results Impress; Motilal Oswal Raises Estimates On Improving Auto Margins
On the back of its healthy launch pipeline and positive consumer sentiment, M&M provided a strong outlook for FY27E across segments, believes the brokerage.
-
Titan Q2 Review: Target Price Cut Doesn't Diminish Motilal Oswal's Bullish View | Here's Why
The brokerage remains constructive on growth in the jewelry industry, particularly among top players, and believe Titan will remain well-positioned competitively, supported by initiatives such as its exchange program.
-
Diwali Muhurat Picks 2026: Eternal, Titan Among Motilal Oswal's Top 10 Stock Bets For Samvat 2083
For Samvat 2083, the brokerage is positive on BFSI and capital markets, manufacturing, global outsourcing, exports, and consumption and digital. Banks are set for steady loan growth with improving margins, while rising participation supports capital markets segment.
-
Eating More Carbs May Help Reverse Biological Ageing: What A New Study Says
A University of Sydney study found older adults on a low-fat, high-carb omnivorous diet showed improved biological-age markers in four weeks.
-
Redington Gets Motilal Oswal's 'Buy' Initiation, Sees Up To 36% Upside; Check Target Price
Redington is well positioned to capitalise on structural growth in technology distribution, supported by established original equipment manufacturer relationships, an extensive channel network and a diversified geographic presence, believes Motilal Oswal.
-
Mahanagar Gas To Fine Organic Q2 Review: Check Motilal Oswal's New Target Prices, Upside
Following September-quarter earnings, domestic brokerage Motilal Oswal has maintained its ratings on all seven stocks across pharma, building material, retail, oil and gas sector including Mahanagar Gas, GSK Pharma, V2 Retail, Anant Raj, and more with uspide of up to 48%.
-
Nykaa, Zydus Lifesciences And More Q2 Review: HDFC Sec Sees Up To 83% Upside Across 17 Stocks; Check New Target Prices
Following September-quarter earnings, HDFC Sec has maintained its ratings on 17 stocks across pharma, capital markets, financial services, healthcare, retail, chemicals, including Zydus Life, BSE, Nykaa, Lupin, MCX, Sundaram Finance, HG Infra and more.
-
Dabur Q2 Review: Sustaining Earnings Growth Key For Valuations, Says HDFC Securities; Check Target Price
Clear strategic actions under the new leadership will be critical to sustaining the early momentum and supporting Dabur's valuation recovery, says the brokerage.
-
Lenskart Q2 Review: Motilal Oswal Raises Target Price As Growth, Margins Improve
India revenue growth accelerated to 35% YoY driven by robust same-store sales growth and store additions, while Lenskart's international business delivered a strong quarter.
-
Lupin Q2 Review: Systematix Revises Target Price, Remains Cautious On US Recovery
While the growing complex generics, injectables and biosimilars pipeline provides medium-term growth visibility, Systematix remain cautious on Lupin's near-term US trajectory, given continued competitive intensity in Tolvaptan and Mirabegron.
-
Delhi HC Issues Notice On Plea Seeking Time-Bound Safety Review Of Acidity Drug Ranitidine
The Delhi High Court on Wednesday issued notice on a Public Interest Litigation (PIL) seeking a time-bound and reasoned decision by the Centre on the safety of Ranitidine, a widely used acidity medication, amid concerns over the possible presence of a cancer-linked impurity in the drug.
